Abstract
Atrial fibrillation is the most common clinically significant cardiac arrhythmia and is associated with markedly increased risks of cardiovascular diseases. Atrial fibrillation and hypertension often coexist and are both responsible for considerable morbidity and mortality. Aggressive treatment of hypertension, especially with a blocker of the reninangiotensin system, may postpone or prevent development of atrial fibrillation and reduce thromboembolic complications. Awareness of the risk of developing atrial fibrillation in hypertensives may be of great importance and focus on prevention of atrial fibrillation development with optimal antihypertensive treatment may reduce morbidity, mortality and health care expenditures.
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II type I receptor blockers, atrial fibrillation, hypertension, renin-angiotensin system, cardiac arrhythmia, cardiovascular diseases, thromboembolic complications, Framingham Heart Study, systolic blood pressure, electrocardiogram, ANTIHYPERTEN-SIVE TREATMENT, RAS-blockade, cardiac hypertrophy, left ventricular hypertrophy, beta-blocker, valsartan, calcium channel blockers, (lisinopril), (doxazosin), (chlorthalidone), (losartan), (amlodipine), atenolol/amlodipine, telmisartan, ESH/ESC guidelines, anti-arrhythmic drugs, (ramipril), (irbesartan), myocardial infarction, diltiazem, Diuretics, hydrochlorothiazide, Alpha-Adrenoreceptor Blocker
Current Vascular Pharmacology
Title: A Link Between Hypertension and Atrial Fibrillation: Methods of Treatment and Prevention
Volume: 8 Issue: 6
Author(s): Tonje A. Aksnes and Sverre E. Kjeldsen
Affiliation:
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II type I receptor blockers, atrial fibrillation, hypertension, renin-angiotensin system, cardiac arrhythmia, cardiovascular diseases, thromboembolic complications, Framingham Heart Study, systolic blood pressure, electrocardiogram, ANTIHYPERTEN-SIVE TREATMENT, RAS-blockade, cardiac hypertrophy, left ventricular hypertrophy, beta-blocker, valsartan, calcium channel blockers, (lisinopril), (doxazosin), (chlorthalidone), (losartan), (amlodipine), atenolol/amlodipine, telmisartan, ESH/ESC guidelines, anti-arrhythmic drugs, (ramipril), (irbesartan), myocardial infarction, diltiazem, Diuretics, hydrochlorothiazide, Alpha-Adrenoreceptor Blocker
Abstract: Atrial fibrillation is the most common clinically significant cardiac arrhythmia and is associated with markedly increased risks of cardiovascular diseases. Atrial fibrillation and hypertension often coexist and are both responsible for considerable morbidity and mortality. Aggressive treatment of hypertension, especially with a blocker of the reninangiotensin system, may postpone or prevent development of atrial fibrillation and reduce thromboembolic complications. Awareness of the risk of developing atrial fibrillation in hypertensives may be of great importance and focus on prevention of atrial fibrillation development with optimal antihypertensive treatment may reduce morbidity, mortality and health care expenditures.
Export Options
About this article
Cite this article as:
A. Aksnes Tonje and E. Kjeldsen Sverre, A Link Between Hypertension and Atrial Fibrillation: Methods of Treatment and Prevention, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563807
DOI https://dx.doi.org/10.2174/157016110793563807 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology Modified-Release Solid Formulations for Colonic Delivery
Recent Patents on Drug Delivery & Formulation Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Clinical Research in India - Current Scenario and the Need of the Hour
Applied Clinical Research, Clinical Trials and Regulatory Affairs Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Flavonoid-Enriched Extract from Desert Plant Warionia saharae Improves Glucose and Cholesterol Levels in Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Protein and Peptide Biopharmaceuticals: An Overview
Protein & Peptide Letters Clinical Approach for the Treatment of Obesity-associated Diseases
Current Pharmaceutical Design Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology Meet Our Editor:
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Gender-Dependent Levels of Hyaluronic Acid in Cerebrospinal Fluid of Patients with Neurodegenerative Dementia
Current Alzheimer Research Post Dural Puncture Headache and Hypertension
Current Hypertension Reviews Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design Association Between Adiposity Indices and Blood Pressure is Stronger in Sarcopenic Obese Women
Current Hypertension Reviews Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer’s disease
Central Nervous System Agents in Medicinal Chemistry The Importance of Alkynyl Chain Presence for the Activity of Adenine Nucleosides/Nucleotides on Purinergic Receptors
Current Medicinal Chemistry Modulation of Staurosporine-Activated Volume-Sensitive Outwardly Rectifying Cl- Channel by PI3K/Akt in Cardiomyocytes
Current Pharmaceutical Design Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Markers of Early Vascular Ageing
Current Pharmaceutical Design